In Vitro and In Vivo Testing of 177Lu-DOTA-Nimotuzumab, a Potential Radioimmunotherapeutical Agent of Cancers-Reference-Cited by-同舟云学术

In Vitro and In Vivo Testing of 177Lu-DOTA-Nimotuzumab, a Potential Radioimmunotherapeutical Agent of Cancers

Published:2012-12 Issue:4 Volume:44 Page:333-345
ISSN:1978-3043
Container-title:ITB Journal of Sciences
language:
Short-container-title:itbj.sci.

Author:

Ramli Martalena, ,Hidayat Basuki,Rustendi Cecep Taufik,Subur Muhammad,Ardiyatno Cahya Nova,Karyadi Karyadi,Aguswarini Sri,Humani Titis Sekar,Ritawidya Rien,Mutalib Abdul,Masjhur Johan S.

Publisher

The Institute for Research and Community Services (LPPM) ITB

Subject

Multidisciplinary

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of polyethylene glycol-modified gold nanoparticles for the delivery of Lutetium-177- radiopharmaceuticals based on antibodies;Journal of Drug Delivery Science and Technology;2024-10

2. Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer;Advanced Pharmaceutical Bulletin;2023-04-29

3. 90Y-DOTA-nimotuzumab: Synthesis of a Promising β⁻ radiopharmaceutical;Current Radiopharmaceuticals;2021-01-04

4. First individualized patient dosimetry in radionuclide therapy with 177Lu-PSMA-CC34 in Indonesia;PROCEEDINGS OF INTERNATIONAL CONFERENCE ON NUCLEAR SCIENCE, TECHNOLOGY, AND APPLICATION 2020 (ICONSTA 2020);2021

5. Implementation of dosimetry protocol for radionuclide therapy in Indonesia: Collaborative works in nuclear medicine;PROCEEDINGS OF THE INTERNATIONAL CONFERENCE AND SCHOOL ON PHYSICS IN MEDICINE AND BIOSYSTEM (ICSPMB): Physics Contribution in Medicine and Biomedical Applications;2021